Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Backs Pfizer’s Xalkori In Lung Cancer After Firm Cuts Price (Again)

Executive Summary

Pfizer’s oral therapy Xalkori (criotinib) for ALK-positive non-small cell lung cancer wins backing by the UK HTA after drug maker offers bigger discount than previously made and more supporting data.

You may also be interested in...

UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs

Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.

Pfizer Laments Price Cut Needed To Secure Xalkori NICE Yes

Pfizer warns that price cuts are unsustainable as UK HTA NICE gives provisional backing to Xalkori and Novartis' Afinitor. The drug makers had offered additional, undisclosed price cuts for their cancer therapies.

Pfizer's Xalkori rides on in first-line NSCLC

Pfizer is now poised to tout its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) as a standard of care in both the first and second-line setting for patients with ALK-positive advanced non-small-cell lung cancer (NSCLC), following positive results in the Phase III PROFILE 1014 study.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts